23 Ces Urol 2022; 26(1): 13–28 PŘEHLEDOVÉ ČLÁNKY 20. Singla N, Hutchinson RC, Ghandour RA, et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol Semin Orig Investig. 2020; 38(6): 604.e9–604.e17. doi:10.1016/j.urolonc.2020. 02. 029. 21. Bakouny Z, Xie W, Dudani S, et al. Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score‑based analysis. J Clin Oncol. 2020; 38(6_suppl): 608–608. doi:10.1200/JCO.2020. 38. 6_suppl.608. 22. Poprach A, Holanek M, Chloupkova R, et al. Cytoreductive Nephrectomy and Overall Survival of Pa‑ tients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy–Data from the National Renis Registry. Cancers (Basel). 2020; 12(10): 2911. doi:10.3390/cancers12102911. 23. Ljungberg B, Albiges L, Abu‑Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019; 75(5): 799–810. doi:10.1016/j.eururo.2019. 02. 011. 24. Mejean A, Thezenas S, Chevreau C, et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC‑risk population. J Clin Oncol. 2019; 37(15_suppl): 4508–4508. doi:10.1200/JCO.2019. 37. 15_suppl.4508. 25. Heng DYC, Wells JC, Rini BI, et al. Cytoreductive Nephrectomy in Patients with Synchronous Metasta‑ ses from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014; 66(4): 704–710. doi:10.1016/j.eururo.2014. 05. 034. 26. Silagy AW, Kotecha RR, Weng S, et al. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer. 2021; 127(21): 3946–3956. doi:10.1002/cncr.33790 27. Shuch B, La Rochelle JC, Wu J, et al. Performance status and cytoreductive nephrectomy. Cancer. 2008; 113(6): 1324–1331. doi:10.1002/cncr.23708. 28. Ohno Y, Nakashima J, Ohori M, et al. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil‑to‑lymphocyte ratio and performance status. Int J Clin Oncol. 2014; 19(1): 139–145. doi:10.1007/s10147-012-0514-5. 29. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC. Outcome after cytore‑ ductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007; 100(4): 755–759. doi:10.1111/j.1464-410X.2007.07108.x. 30. Capitanio U, Abdollah F, Matloob R, et al. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. Int J Urol. 2013; 20(6): 572–579. doi:10.1111/iju.12004. 31. Yoon H‑J, Paeng JC, Kwak C, et al. Prognostic implication of extrarenal metabolic tumor burden in advanced renal cell carcinoma treated with targeted therapy after nephrectomy. Ann Nucl Med. 2013; 27(8): 748–755. doi:10.1007/s12149-013-0742-4. 32. de Bruijn RE, Nijkamp J, Noe A, et al. Baseline tumor volume in assessing prognosis of patients with intermediate‑risk synchronous metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2016; 34(6): 258.e7–258.e13. doi:10.1016/j.urolonc.2015. 12. 007. 33. Blute ML, Ziemlewicz TJ, Lang JM, et al. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Ana‑ lysis. Urology. 2017; 100: 139–144. doi:10.1016/j.urology.2016. 09. 016. 34. Guo B, Liu S, Wang M, Hou H, Liu M. The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis. Bosn J Basic Med Sci. July 2020. doi:10.17305/bjbms.2020.4896. 35. Massari F, Di Nunno V, Guida A, et al. Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clin Genitourin Cancer. 2021; 19(1): 32–40. doi:10.1016/j.clgc.2020. 06. 003.
RkJQdWJsaXNoZXIy NDA4Mjc=